Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 2
Update on terbinafine with a focus on dermatophytoses
Authors Newland JG, Abdel-Rahman S
Published 21 April 2009 Volume 2009:2 Pages 49—63
DOI https://doi.org/10.2147/CCID.S3690
Review by Single anonymous peer review
Peer reviewer comments 3
Jason G Newland1,3, Susan M Abdel-Rahman2,3
Divisions of Infectious Diseases1 and Clinical Pharmacology and Medical Toxicology2, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA; 3Department of Pediatrics, University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA
Abstract: Since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungal infections, aided by unique pharmacologic and microbiologic profiles. This article reviews mode of action, antimycotic spectrum and disposition profile of terbinafine. It examines the data, accumulated over 15 years, on the comparative efficacy of terbinafine (vs griseofulvin, itraconazole, fluconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.
Keywords: tinea, Trichophyton, Microsporum, allylamine, antifungal
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.